Increases in medicare prescription drug plan costs attributable to psychotropic medications

Kara Zivin, Ryan J. McCammon, Matthew M. Davis, Lakshmi K. Halasyamani, Helen C. Kales

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Older patients may regard some medications, particularly psychotropic medications, as discretionary compared with what they perceive as more "essential" nonpsychiatric medications. Patients concerns about psychotropic medication costs under Medicare Part D may reinforce these impressions. Design: The authors examined which Medicare prescription drug plans (PDPs) would be least expensive for beneficiaries considering the costs of 1) all medications; and 2) only nonpsychiatric medications. Setting: The authors collected data from the PDP online comparison tool provided by the Centers for Medicare and Medicaid Services (CMS). Participants: Hypothetical Medicare beneficiaries. Measurements: The authors examined four clinical scenarios from older outpatients with both chronic medical and psychiatric conditions (including psychosis, bipolar disorder, depression, and dementia with behavioral disturbances). Results: The authors examined data from all 160 plans available in CMS PDP regions in May 2007. There were frequent discrepancies in the least expensive PDPs within region, depending on considering the costs of all medications, or just nonpsychiatric medications. In the clinical scenarios, patients selecting a PDP based on nonpsychiatric medications alone would pick an unnecessarily more expensive plan 74%ĝ€"100% of the time (when they took any brand name medication), suggesting that excluding psychiatric medications from PDP choices may be excessively costly. However, brand name psychotropic medications significantly increased the costs of the least expensive plans. The latter finding might persuade patients to avoid taking needed psychiatric medication due to cost. CONCLUSION:: This research highlights the complexity that patients with psychiatric and cognitive disorders face when choosing a Medicare PDP. Policymakers and clinicians should be aware of the tradeoffs that beneficiaries with psychiatric disorders face when making PDP plan choices.

Original languageEnglish (US)
Pages (from-to)674-685
Number of pages12
JournalAmerican Journal of Geriatric Psychiatry
Volume16
Issue number8
DOIs
StatePublished - Aug 2008
Externally publishedYes

Fingerprint

Drug Costs
Prescription Drugs
Medicare
Psychiatry
Costs and Cost Analysis
Centers for Medicare and Medicaid Services (U.S.)
Bipolar Disorder
Names
Medicare Part D
Psychotic Disorders
Dementia
Outpatients
Research

Keywords

  • Bipolar disorder psychosis
  • Dementia
  • Depression
  • Medicare prescription drug plan
  • Prescription medication

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Increases in medicare prescription drug plan costs attributable to psychotropic medications. / Zivin, Kara; McCammon, Ryan J.; Davis, Matthew M.; Halasyamani, Lakshmi K.; Kales, Helen C.

In: American Journal of Geriatric Psychiatry, Vol. 16, No. 8, 08.2008, p. 674-685.

Research output: Contribution to journalArticle

Zivin, Kara ; McCammon, Ryan J. ; Davis, Matthew M. ; Halasyamani, Lakshmi K. ; Kales, Helen C. / Increases in medicare prescription drug plan costs attributable to psychotropic medications. In: American Journal of Geriatric Psychiatry. 2008 ; Vol. 16, No. 8. pp. 674-685.
@article{0544b0b2c7314ac79b4aa27e562bcb92,
title = "Increases in medicare prescription drug plan costs attributable to psychotropic medications",
abstract = "Objective: Older patients may regard some medications, particularly psychotropic medications, as discretionary compared with what they perceive as more {"}essential{"} nonpsychiatric medications. Patients concerns about psychotropic medication costs under Medicare Part D may reinforce these impressions. Design: The authors examined which Medicare prescription drug plans (PDPs) would be least expensive for beneficiaries considering the costs of 1) all medications; and 2) only nonpsychiatric medications. Setting: The authors collected data from the PDP online comparison tool provided by the Centers for Medicare and Medicaid Services (CMS). Participants: Hypothetical Medicare beneficiaries. Measurements: The authors examined four clinical scenarios from older outpatients with both chronic medical and psychiatric conditions (including psychosis, bipolar disorder, depression, and dementia with behavioral disturbances). Results: The authors examined data from all 160 plans available in CMS PDP regions in May 2007. There were frequent discrepancies in the least expensive PDPs within region, depending on considering the costs of all medications, or just nonpsychiatric medications. In the clinical scenarios, patients selecting a PDP based on nonpsychiatric medications alone would pick an unnecessarily more expensive plan 74{\%}ĝ€{"}100{\%} of the time (when they took any brand name medication), suggesting that excluding psychiatric medications from PDP choices may be excessively costly. However, brand name psychotropic medications significantly increased the costs of the least expensive plans. The latter finding might persuade patients to avoid taking needed psychiatric medication due to cost. CONCLUSION:: This research highlights the complexity that patients with psychiatric and cognitive disorders face when choosing a Medicare PDP. Policymakers and clinicians should be aware of the tradeoffs that beneficiaries with psychiatric disorders face when making PDP plan choices.",
keywords = "Bipolar disorder psychosis, Dementia, Depression, Medicare prescription drug plan, Prescription medication",
author = "Kara Zivin and McCammon, {Ryan J.} and Davis, {Matthew M.} and Halasyamani, {Lakshmi K.} and Kales, {Helen C.}",
year = "2008",
month = "8",
doi = "10.1097/JGP.0b013e3181794591",
language = "English (US)",
volume = "16",
pages = "674--685",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Increases in medicare prescription drug plan costs attributable to psychotropic medications

AU - Zivin, Kara

AU - McCammon, Ryan J.

AU - Davis, Matthew M.

AU - Halasyamani, Lakshmi K.

AU - Kales, Helen C.

PY - 2008/8

Y1 - 2008/8

N2 - Objective: Older patients may regard some medications, particularly psychotropic medications, as discretionary compared with what they perceive as more "essential" nonpsychiatric medications. Patients concerns about psychotropic medication costs under Medicare Part D may reinforce these impressions. Design: The authors examined which Medicare prescription drug plans (PDPs) would be least expensive for beneficiaries considering the costs of 1) all medications; and 2) only nonpsychiatric medications. Setting: The authors collected data from the PDP online comparison tool provided by the Centers for Medicare and Medicaid Services (CMS). Participants: Hypothetical Medicare beneficiaries. Measurements: The authors examined four clinical scenarios from older outpatients with both chronic medical and psychiatric conditions (including psychosis, bipolar disorder, depression, and dementia with behavioral disturbances). Results: The authors examined data from all 160 plans available in CMS PDP regions in May 2007. There were frequent discrepancies in the least expensive PDPs within region, depending on considering the costs of all medications, or just nonpsychiatric medications. In the clinical scenarios, patients selecting a PDP based on nonpsychiatric medications alone would pick an unnecessarily more expensive plan 74%ĝ€"100% of the time (when they took any brand name medication), suggesting that excluding psychiatric medications from PDP choices may be excessively costly. However, brand name psychotropic medications significantly increased the costs of the least expensive plans. The latter finding might persuade patients to avoid taking needed psychiatric medication due to cost. CONCLUSION:: This research highlights the complexity that patients with psychiatric and cognitive disorders face when choosing a Medicare PDP. Policymakers and clinicians should be aware of the tradeoffs that beneficiaries with psychiatric disorders face when making PDP plan choices.

AB - Objective: Older patients may regard some medications, particularly psychotropic medications, as discretionary compared with what they perceive as more "essential" nonpsychiatric medications. Patients concerns about psychotropic medication costs under Medicare Part D may reinforce these impressions. Design: The authors examined which Medicare prescription drug plans (PDPs) would be least expensive for beneficiaries considering the costs of 1) all medications; and 2) only nonpsychiatric medications. Setting: The authors collected data from the PDP online comparison tool provided by the Centers for Medicare and Medicaid Services (CMS). Participants: Hypothetical Medicare beneficiaries. Measurements: The authors examined four clinical scenarios from older outpatients with both chronic medical and psychiatric conditions (including psychosis, bipolar disorder, depression, and dementia with behavioral disturbances). Results: The authors examined data from all 160 plans available in CMS PDP regions in May 2007. There were frequent discrepancies in the least expensive PDPs within region, depending on considering the costs of all medications, or just nonpsychiatric medications. In the clinical scenarios, patients selecting a PDP based on nonpsychiatric medications alone would pick an unnecessarily more expensive plan 74%ĝ€"100% of the time (when they took any brand name medication), suggesting that excluding psychiatric medications from PDP choices may be excessively costly. However, brand name psychotropic medications significantly increased the costs of the least expensive plans. The latter finding might persuade patients to avoid taking needed psychiatric medication due to cost. CONCLUSION:: This research highlights the complexity that patients with psychiatric and cognitive disorders face when choosing a Medicare PDP. Policymakers and clinicians should be aware of the tradeoffs that beneficiaries with psychiatric disorders face when making PDP plan choices.

KW - Bipolar disorder psychosis

KW - Dementia

KW - Depression

KW - Medicare prescription drug plan

KW - Prescription medication

UR - http://www.scopus.com/inward/record.url?scp=54549085521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54549085521&partnerID=8YFLogxK

U2 - 10.1097/JGP.0b013e3181794591

DO - 10.1097/JGP.0b013e3181794591

M3 - Article

C2 - 18669946

AN - SCOPUS:54549085521

VL - 16

SP - 674

EP - 685

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 8

ER -